Related Experiment Video
Updated: Nov 5, 2025

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
Treatment of mild-to-moderate hypertriglyceridemia.
Pablo Pérez-Martínez1, Francisco Pérez-Jiménez1
1Unidad de Lípidos y Arterioesclerosis, Universidad de Córdoba/Hospital Universitario Reina Sofía/Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, España; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, España.
Managing mild-moderate hypertriglyceridaemia (HTG) involves lifestyle changes and medications to lower cardiovascular risk. The goal is to reduce triglycerides (TG) and LDL-cholesterol (LDL-C), improving lipid profiles for better heart health.
Area of Science:
- Cardiology
- Metabolic Disorders
- Pharmacology
Background:
- Triglycerides (TG) play a role in cardiovascular risk, with hypertriglyceridaemia (HTG) being a complex metabolic condition.
- HTG is associated with increased risk of atherosclerosis and other cardiovascular events.
Purpose of the Study:
- To discuss current recommendations for managing mild-moderate hypertriglyceridaemia (150-880 mg/dL).
- To outline strategies for reducing cardiovascular risk by controlling HTG and lowering LDL-cholesterol (LDL-C).
Main Methods:
- Review of current clinical guidelines and therapeutic approaches for HTG.
- Discussion of lifestyle modifications and pharmacological interventions.
Main Results:
- Management aims to decrease LDL-cholesterol (LDL-C), control HTG, reduce TG-rich lipoproteins (TRLs), and improve HDL-cholesterol (HDL-C).
- Key lipid targets include lowering apoprotein B (ApoB) and non-HDL-cholesterol (non-HDL-C).
Conclusions:
- A multi-faceted approach combining lifestyle changes and pharmacotherapy is essential for managing mild-moderate HTG.
- Effective management can mitigate the atherogenic role of TG and reduce overall cardiovascular risk.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Angina IV: Management

